The purpose of this funding opportunity (FOA) is to stimulate research on the identification of new and novel targets and mechanisms involved in tumor immune evasion, which may be amenable to analysis by small molecules, pharmacological, or molecular genetics approaches. A specific focus of this FOA is to encourage cross disciplinary collaborations between immunologists, cell biologists, medicinal chemists, pharmacologists, and molecular biologists.
There is another related FOA that is suitable for R01 research projects whose goals relate to the goals of this FOA, but differ in scope - PAR-17-331: Discovery of Small Molecule Immunomodulators for Cancer Therapy (R01).
Deadlines:
PAR-17-330 Expiration Date New Date September 8, 2020 per issuance of NOT-CA-17-076. (Original Expiration Date: May 8, 2020)
